Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Kathleen Roberge
Observed institution:
Trillium Therapeutics (Canada)
OpenAlex ID:
A5080209757
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
2021
·
Stephen M. Ansell
, Michael B. Maris
, et al.
·
Clinical Cancer Research
·
205
PDF
Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study
2020
·
Krish Patel
, Radhakrishnan Ramchandren
, et al.
·
Blood
·
17
An open-label, multicenter study of DPTX3186 to evaluate safety, tolerability, and pharmacokinetics in subjects with known Wnt pathway–activated solid tumors where no other treatments exist.
2026
·
Alexander I. Spira
, Karl Hsu
, et al.
·
Journal of Clinical Oncology
Supplemental Figure 1 from Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
2023
·
Stephen M. Ansell
, Michael B. Maris
, et al.
Data from Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
2023
·
Stephen M. Ansell
, Michael B. Maris
, et al.
Data from Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
2023
·
Stephen M. Ansell
, Michael B. Maris
, et al.
Supplemental Figure 1 from Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
2023
·
Stephen M. Ansell
, Michael B. Maris
, et al.
PDF
Show more works
View as search
Works count:
7
Citation count:
222
H-index:
2
I10-index:
2
Year
Topic
Type
